CRISPRi在结核分枝杆菌生物学研究中的应用及优化  

Application and optimization of CRISPRi to the biology of Mycobacterium tuberculosis

作　　者：Le Thi Thu Thuy 黄煜 谢建平[1] Le Thi Thu Thuy;Huang Yu;Xie Jianping(School of Life Sciences,Institute of Modern Biopharmaceuticals,Southwest University,Chongqing 400715,China)

机构地区：[1]西南大学生命科学学院现代生物医药研究所,重庆400715

出　　处：《中华结核和呼吸杂志》2024年第4期376-382,共7页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：结核分枝杆菌(MTB)感染导致的结核病仍然是全球公共卫生的巨大挑战。耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)菌株使得结核病治疗更加困难。不断研发新遗传工具,探索MTB生理,有望发现新的药物靶点。其中,最近用于MTB研究的成簇规律间隔短回文重复序列干扰(CRISPRi)与高通量测序相结合,为揭示MTB生理和遗传提供了基础。本文综述了CRISPRi在MTB生物学研究中的应用及技术发展。Tuberculosis,caused by infection with Mycobacterium tuberculosis(MTB),remains a global public health challenge.Multidrug-resistant tuberculosis(MDR-TB)and extensively drug-resistant tuberculosis(XDR-TB)strains make tuberculosis more difficult to control.New tools to study the biology of MTB can identify novel targets for drug discovery.Recently,the Clustered Regularly Interspaced Short Palindromic Repeats interference(CRISPRi)combined with next-generation sequencing has provided many novel insights into the physiology and genetics of MTB.This review summarizes the application and optimization of CRISPRi in MTB biology.

关 键 词：结核病治疗 耐多药结核病 全球公共卫生 结核分枝杆菌 广泛耐药结核病 药物靶点 成簇规律间隔短回文重复序列 高通量测序 

分 类 号：R52[医药卫生—内科学]